Nature Medicine has published an author correction for a significant phase 1 clinical trial investigating MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager therapy in patients with recurrent and refractory solid tumours. The correction, released online on 19 June 2026, addresses specific data and methodological clarifications in the original trial report.
This correction underscores the commitment to scientific integrity within the peer-reviewed research community. The MAGE-A4/A8 immunotherapy represents a novel approach to treating difficult-to-treat malignancies by leveraging T cell engager technology—a synthetic immunotherapy designed to simultaneously bind cancer antigens and T cell receptors.
The publication of corrections in peer-reviewed journals demonstrates the self-correcting mechanisms inherent in rigorous clinical research and maintains the credibility of cancer immunotherapy investigations. Read the full article on GMJ Newsroom.
Was this article helpful?
